ADC Therapeutics shares are trading lower after the company announced topline data from its Phase 3 LOTIS-5 confiramtory trial evaluating ZYLNLONTA in combination with rituximab. The company indicated that LOTIS-5 showed elevated serious and Grade 5 adverse events and it will discuss the benefit-risk profile with the FDA.